Copyright
©The Author(s) 2025.
World J Gastrointest Surg. Jul 27, 2025; 17(7): 106487
Published online Jul 27, 2025. doi: 10.4240/wjgs.v17.i7.106487
Published online Jul 27, 2025. doi: 10.4240/wjgs.v17.i7.106487
Table 1 Comparison of baseline data between the control group and the observation group
Characteristic | Control group (n = 54) | Observation group (n = 26) | χ2/t | P value | |
Age (mean ± SD, years) | 68.85 ± 1.26 | 68.33 ± 1.12 | 1.790 | 0.077 | |
Gender | Male | 41 (75.93) | 22 (84.62) | 0.792 | 0.374 |
Female | 13 (24.07) | 4 (15.38) | |||
Tumor location | Gastric antrum or pylorus | 39 (72.22) | 18 (69.23) | 0.315 | 0.753 |
Stomach body | 8 (14.81) | 3 (11.54) | |||
Gastric fundus or cardia | 7 (12.97) | 5 (19.23) | |||
Clinical staging | Phase II | 23 (42.59) | 16 (61.54) | 2.521 | 0.112 |
Phase III | 31 (57.41) | 10 (38.46) | |||
Surgical scope | Partial excision | 25 (46.30) | 17 (65.38) | 2.564 | 0.109 |
Fully cut | 29 (53.70) | 9 (24.62) | |||
Tumor size | < 2 cm | 8 (14.81) | 7 (26.92) | 0.672 | 0.502 |
2-5 cm | 36 (66.67) | 14 (53.85) | |||
> 5 cm | 10 (18.52) | 5 (19.23) | |||
Degree of differentiation | High | 2 (3.70) | 2 (7.69) | 0.455 | 0.649 |
In | 16 (29.63) | 8 (30.77) | |||
Low | 36 (66.67) | 16 (61.54) | |||
Smoke | Have | 23 (42.59) | 10 (38.46) | 0.124 | 0.725 |
Without | 31 (57.41) | 16 (61.54) | |||
Drink | Have | 36 (66.67) | 19 (73.08) | 0.336 | 0.562 |
Without | 18 (33.33) | 7 (26.92) | |||
Hypertension | Have | 22 (40.74) | 14 (53.85) | 1.218 | 0.270 |
Without | 32 (59.26) | 12 (46.15) | |||
Diabetes mellitus | Have | 17 (31.48) | 13 (50.00) | 2.568 | 0.109 |
Without | 37 (68.52) | 13 (50.00) |
Table 2 Clinical efficacy
Group | CR | PR | SD | PD | ORR | DCR |
Control group (n = 54) | 11 (20.37) | 14 (25.93) | 13 (24.07) | 16 (29.63) | 25 (46.30) | 38 (70.37) |
Observation group (n = 26) | 13 (50.00) | 9 (34.62) | 2 (7.69) | 2 (7.69) | 22 (84.62) | 24 (92.31) |
χ2/t | - | - | - | - | 10.634 | 4.844 |
P value | - | - | - | - | 0.001 | 0.028 |
Table 3 Comparison of clinical data of patients with different curative effects
Characteristic | Total number of cases (n = 80) | Effective (n = 62) | Invalid (n = 18) | χ2/t | P value | |
Use Baohe Pingwei powder | 26 (32.50) | 24 (38.71) | 2 (11.11) | 4.843 | 0.029 | |
Age (mean ± SD, years) | 68.51 ± 1.94 | 68.67 ± 2.13 | 68.02 ± 2.04 | 1.150 | 0.254 | |
Gender | Male | 63 (78.75) | 50 (80.65) | 13 (72.22) | 0.195 | 0.659 |
Female | 17 (21.25) | 12 (19.35) | 5 (27.78) | |||
Tumor location | Gastric antrum or pylorus | 57 (71.25) | 45 (72.58) | 12 (66.67) | 0.456 | 0.648 |
Stomach body | 11 (13.75) | 8 (12.90) | 3 (16.67) | |||
Gastric fundus or cardia | 12 (15.00) | 9 (14.52) | 3 (16.67) | |||
Clinical staging | Phase II | 39 (48.75) | 31 (50.00) | 8 (44.44) | 0.172 | 0.678 |
Phase III | 41 (51.25) | 31 (50.00) | 10 (55.56) | |||
Surgical scope | Partial excision | 42 (52.50) | 33 (53.23) | 9 (50.00) | 0.058 | 0.809 |
Fully cut | 38 (47.50) | 29 (46.77) | 9 (50.00) | |||
Tumor size | < 2 cm | 15 (18.75) | 13 (20.97) | 2 (11.11) | 2.172 | 0.030 |
2-5 cm | 50 (62.50) | 41 (66.13) | 9 (50.00) | |||
> 5 cm | 15 (18.75) | 8 (12.90) | 7 (38.89) | |||
Degree of differentiation | High | 4 (5.00) | 2 (3.23) | 2 (11.11) | 2.675 | 0.008 |
In | 24 (30.00) | 15 (24.19) | 9 (50.00) | |||
Low | 52 (65.00) | 45 (72.58) | 7 (38.89) | |||
Smoke | Have | 33 (41.25) | 27 (43.55) | 6 (33.33) | 0.601 | 0.438 |
Without | 47 (58.75) | 35 (56.45) | 12 (66.67) | |||
Drink | Have | 55 (68.75) | 44 (70.97) | 11 (61.11) | 0.601 | 0.427 |
Without | 25 (31.25) | 18 (29.03) | 7 (38.89) | |||
Hypertension | Have | 36 (45.00) | 26 (41.94) | 10 (55.56) | 1.667 | 0.197 |
Without | 44 (55.00) | 37 (59.68) | 7 (38.89) | |||
Diabetes mellitus | Have | 30 (37.50) | 24 (38.71) | 6 (33.33) | 0.172 | 0.678 |
Without | 50 (62.50) | 38 (61.29) | 12 (66.67) | |||
CD3+ (mean ± SD, %) | Before treatment | 56.59 ± 1.67 | 57.36 ± 2.34 | 56.84 ± 2.01 | 0.0855 | 0.395 |
After treatment | 37.34 ± 1.58 | 45.67 ± 2.03 | 32.16 ± 1.35 | 26.521 | 0.000 | |
CD4+ (mean ± SD, %) | Before treatment | 39.46 ± 1.26 | 39.15 ± 2.06 | 40.12 ± 2.37 | 1.700 | 0.082 |
After treatment | 25.64 ± 1.03 | 30.58 ± 1.64 | 21.34 ± 1.42 | 21.642 | 0.000 | |
CA19-9 (mean ± SD, %) | Before treatment | 71.69 ± 2.45 | 71.64 ± 2.43 | 72.87 ± 2.16 | 1.935 | 0.057 |
After treatment | 36.98 ± 2.06 | 35.69 ± 1.26 | 38.59 ± 2.16 | 7.207 | 0.000 | |
CA242 (U/mL) | Before treatment | 44.27 ± 0.28 | 44.17 ± 0.25 | 44.15 ± 0.03 | 0.337 | 0.737 |
After treatment | 26.31 ± 1.34 | 37.12 ± 2.13 | 12.24 ± 0.15 | 49.299 | 0.000 | |
IL-6 (mean ± SD, ng/mL) | Before treatment | 428.94 ± 2.69 | 429.67 ± 2.16 | 429.32 ± 2.15 | 0.606 | 0.546 |
After treatment | 317.65 ± 2.36 | 310.84 ± 2.67 | 328.12 ± 2.37 | 24.751 | 0.000 | |
IL-10 (mean ± SD, ng/mL) | Before treatment | 92.84± 1.52 | 92.98 ± 1.76 | 92.48 ± 1.38 | 1.109 | 0.271 |
After treatment | 234.18 ± 2.68 | 61.08 ± 1.26 | 86.41 ± 1.28 | 74.824 | 0.000 | |
TNF-α (mean ± SD, ng/mL) | Before treatment | 321.23 ± 2.03 | 321.08 ± 0.99 | 321.54 ± 2.31 | 1.237 | 0.220 |
After treatment | 261.33 ± 2.07 | 220.09 ± 1.28 | 319.26 ± 2.17 | 243.829 | 0.000 |
Table 4 Univariate and multivariate analysis
Influence factor | Univariate | Multivariate | ||
HR (95%CI) | P value | HR (95%CI) | P value | |
Tumor size | 1.354 (1.264-1.469) | 0.071 | - | - |
Degree of differentiation | 1.352 (1.028-1.574) | 0.028 | 1.282 (1.019-1.408) | 0.135 |
CD3+ | 0.726 (0.628-0.881) | 0.036 | 0.072 (0.011-0.145) | 0.026 |
CD4+ | 0.883 (0.708-0.934) | 0.024 | 0.424 (0.285-0.662) | 0.033 |
Baohe Pingwei powder | 0.528 (0.482-0.711) | 0.037 | 0.233 (0.162-0.378) | 0.019 |
CA19-9 | 1.269 (1.112-1.420) | 0.044 | 1.523 (1.012-1.963) | 0.007 |
CA242 | 1.046 (0.823-1.349) | 0.258 | - | - |
IL-6 | 1.226 (1.022-1.406) | 0.016 | 2.026 (1.929-2.244) | 0.016 |
IL-10 | 1.134 (0.698-1.342) | 0.082 | - | - |
TNF-α | 1.308 (0.896-1.653) | 0.108 | - | - |
Table 5 Cox proportional hazards model
Model 1 | Model 2 | Model 3 | ||||
HR (95%CI) | P value | HR (95%CI) | P value | HR (95%CI) | P value | |
Ineffective group | Ref | Ref | Ref | |||
Effective group | 0.624 (0.437-0.986) | 0.019 | 0.727 (0.421-0.833) | 0.008 | 1.439 (1.208-1.614) | 0.006 |
CD3+ | 0.422 (0.309-0.528) | 0.026 | 0.608 (0.417-0.839) | 0.000 | 0.619 (0.455-0.808) | 0.000 |
CD4+ | 0.122 (0.019-0.321) | 0.021 | 0.218 (0.107-0.474) | 0.044 | 0.344 (0.274-0.541) | 0.042 |
CA199 | 1.242 (1.024-1.842) | 0.005 | 1.789 (1.424-1.872) | 0.028 | 1.678 (1.564-1.971) | 0.004 |
IL-6 | 1.341 (1.276-1.452) | 0.038 | 1.541 (1.442-1.772) | 0.001 | 1.841 (1.652-1.938) | 0.000 |
- Citation: Ma HY, Liu X, Chen YW, Liang J, Wang J, Zhang MM, Yang Q. Baohe Pingwei power plus neoadjuvant chemotherapy for gastric cancer. World J Gastrointest Surg 2025; 17(7): 106487
- URL: https://www.wjgnet.com/1948-9366/full/v17/i7/106487.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v17.i7.106487